Search

Your search keyword '"Al Malki, Monzr"' showing total 845 results
Start Over Author "Al Malki, Monzr"
845 results on '"Al Malki, Monzr"'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

2. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Author

Daver, Naval, Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr, Larson, Richard, Asch, Adam, Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany, Bradley, Terrence, Wang, Eunice, Sweet, Kendra, Kantarjian, Hagop, Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua, Sallman, David, and Jeyakumar, Deepa

Subjects
Humans, Azacitidine, Antibodies, Monoclonal, Humanized, Remission Induction, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols
Abstract

PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with azacitidine in patients with untreated AML ineligible for intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated AML, including TP53-mutant AML, received magrolimab intravenously as an initial dose (1 mg/kg, days 1 and 4), followed by 15 mg/kg once on day 8 and 30 mg/kg once weekly or every 2 weeks as maintenance. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and proportion with complete remission (CR). RESULTS: Eighty-seven patients were enrolled and treated; 72 (82.8%) had TP53 mutations with a median variant allele frequency of 61% (range, 9.8-98.7). Fifty-seven (79.2%) of TP53-mutant patients had European LeukemiaNet 2017 adverse-risk cytogenetics. Patients received a median of 4 (range, 1-39) cycles of treatment. The most common treatment-emergent adverse events included constipation (49.4%), nausea (49.4%), and diarrhea (48.3%). Thirty (34.5%) experienced anemia, and the median hemoglobin change from baseline to first postdose assessment was -0.9 g/dL (range, -3.6 to 2.5 g/dL). Twenty-eight (32.2%) patients achieved CR, including 23 (31.9%) patients with TP53 mutations. The median overall survival in TP53-mutant and wild-type patients were 9.8 months and 18.9 months, respectively. CONCLUSION: Magrolimab with azacitidine was relatively well tolerated with promising efficacy in patients with AML ineligible for intensive induction chemotherapy, including those with TP53 mutations, warranting further evaluation of magrolimab with azacitidine in AML. The phase III randomized ENHANCE-2 (ClinicalTrials.gov identifier: NCT04778397) and ENHANCE-3 (ClinicalTrials.gov identifier: NCT05079230) studies are recruiting frontline patients with AML.

Published
2023

3. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Author

Sallman, David, Al Malki, Monzr, Asch, Adam, Wang, Eunice, Jurcic, Joseph, Bradley, Terrence, Flinn, Ian, Pollyea, Daniel, Kambhampati, Suman, Tanaka, Tiffany, Zeidner, Joshua, Garcia-Manero, Guillermo, Jeyakumar, Deepa, Komrokji, Rami, Lancet, Jeffrey, Kantarjian, Hagop, Gu, Lin, Zhang, Yajia, Tan, Anderson, Chao, Mark, OHear, Carol, Ramsingh, Giridharan, Lal, Indu, Vyas, Paresh, and Daver, Naval

Subjects
Humans, Azacitidine, Myelodysplastic Syndromes, Antibodies, Monoclonal, Humanized, Progression-Free Survival, Leukemia, Myeloid, Acute, Treatment Outcome
Abstract

PURPOSE: Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a dont-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. We report final phase Ib data in patients with untreated higher-risk myelodysplastic syndromes (MDS) treated with magrolimab and azacitidine (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated Revised International Prognostic Scoring System intermediate-/high-/very high-risk MDS received magrolimab intravenously as a priming dose (1 mg/kg) followed by ramp-up to a 30 mg/kg once-weekly or once-every-2-week maintenance dose. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and complete remission (CR) rate. RESULTS: Ninety-five patients were treated. Revised International Prognostic Scoring System risk was intermediate/high/very high in 27%, 52%, and 21%, respectively. Fifty-nine (62%) had poor-risk cytogenetics and 25 (26%) had TP53 mutation. The most common treatment-emergent adverse effects included constipation (68%), thrombocytopenia (55%), and anemia (52%). Median hemoglobin change from baseline to first postdose assessment was -0.7 g/dL (range, -3.1 to +2.4). CR rate and overall response rate were 33% and 75%, respectively. Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. Median overall survival (OS) was not reached with 17.1-month follow-up. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. CONCLUSION: Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. A phase III trial of magrolimab/placebo + azacitidine is ongoing (ClinicalTrials.gov identifier: NCT04313881 [ENHANCE]).

Published
2023

4. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Author

Akahoshi, Yu, Spyrou, Nikolaos, Weber, Daniela, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L. M.

Published
2024
Full Text
View/download PDF

5. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

7. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Author

Desai, Amrita, Samara, Yazeed, Yang, Dongyun, Ball, Brian, Braun, Adam, Koller, Paul, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet, Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Al Malki, Monzr M., Artz, Andrew, Becker, Pamela, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Curtin, Peter, Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

8. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author

Etra, Aaron, El Jurdi, Najla, Katsivelos, Nikolaos, Kwon, Deukwoo, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Kowalyk, Steven, Aguayo-Hiraldo, Paibel, Akahoshi, Yu, Ayuk, Francis, Baez, Janna, Betts, Brian C., Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gleich, Sigrun, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr, MacMillan, Margaret, Pawarode, Attaphol, Quagliarella, Francesco, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Weisdorf, Daniel, Wölfl, Matthias, Young, Rachel, Nakamura, Ryotaro, Ferrara, James L. M., Levine, John E., and Holtan, Shernan

Published
2024
Full Text
View/download PDF

9. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Author

Akahoshi, Yu, Spyrou, Nikolaos, Hoepting, Matthias, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Kasikis, Stelios, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, DeFilipp, Zachariah, Ferrara, James L. M., Levine, John E., and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

10. A Day 14 Endpoint for Acute GVHD Clinical Trials

Author

Spyrou, Nikolaos, Akahoshi, Yu, Kowalyk, Steven, Morales, George, Beheshti, Rahnuma, Aguayo-Hiraldo, Paibel, Al Malki, Monzr M., Ayuk, Francis, Bader, Peter, Baez, Janna, Capellini, Alexandra, Choe, Hannah, DeFilipp, Zachariah, Eder, Matthias, Eng, Gilbert, Etra, Aaron, Gleich, Sigrun, Grupp, Stephan A., Hexner, Elizabeth, Hoepting, Matthias, Hogan, William J., Kasikis, Stelios, Katsivelos, Nikolaos, Khan, Alina, Kitko, Carrie L., Kraus, Sabrina, Kwon, Deukwoo, Merli, Pietro, Portelli, Joseph, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Holler, Ernst, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L.M.

Published
2024
Full Text
View/download PDF

12. Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice.

Author

Lim, Ji, Sargur Madabushi, Srideshikan, Vishwasrao, Paresh, Song, Joo, Abdelhamid, Amr, Ghimire, Hemendra, Vanishree, V, Lamba, Jatinder, Dandapani, Savita, Salhotra, Amandeep, Lemecha, Mengistu, Pierini, Antonio, Zhao, Daohong, Storme, Guy, Holtan, Shernan, Aristei, Cynthia, Schaue, Dorthe, Al Malki, Monzr, and Hui, Susanta

Subjects
DNA damage, aging, bone marrow transplantation, tissue damage, tissue repair, total marrow irradiation
Abstract

Total body irradiation (TBI) is a commonly used conditioning regimen for hematopoietic stem cell transplant (HCT), but dose heterogeneity and long-term organ toxicity pose significant challenges. Total marrow irradiation (TMI), an evolving radiation conditioning regimen for HCT can overcome the limitations of TBI by delivering the prescribed dose targeted to the bone marrow (BM) while sparing organs at risk. Recently, our group demonstrated that TMI up to 20 Gy in relapsed/refractory AML patients was feasible and efficacious, significantly improving 2-year overall survival compared to the standard treatment. Whether such dose escalation is feasible in elderly patients, and how the organ toxicity profile changes when switching to TMI in patients of all ages are critical questions that need to be addressed. We used our recently developed 3D image-guided preclinical TMI model and evaluated the radiation damage and its repair in key dose-limiting organs in young (~8 weeks) and old (~90 weeks) mice undergoing congenic bone marrow transplant (BMT). Engraftment was similar in both TMI and TBI-treated young and old mice. Dose escalation using TMI (12 to 16 Gy in two fractions) was well tolerated in mice of both age groups (90% survival ~12 Weeks post-BMT). In contrast, TBI at the higher dose of 16 Gy was particularly lethal in younger mice (0% survival ~2 weeks post-BMT) while old mice showed much more tolerance (75% survival ~13 weeks post-BMT) suggesting higher radio-resistance in aged organs. Histopathology confirmed worse acute and chronic organ damage in mice treated with TBI than TMI. As the damage was alleviated, the repair processes were augmented in the TMI-treated mice over TBI as measured by average villus height and a reduced ratio of relative mRNA levels of amphiregulin/epidermal growth factor (areg/egf). These findings suggest that organ sparing using TMI does not limit donor engraftment but significantly reduces normal tissue damage and preserves repair capacity with the potential for dose escalation in elderly patients.

Published
2022

13. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

Author

Arslan, Shukaib, Desai, Amrita, Yang, Dongyun, Mokhtari, Sally, Tiemann, Katrin, Otoukesh, Salman, Samara, Yazeed, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Aribi, Ahmed, Becker, Pamela, Curtin, Peter, Artz, Andrew, Aldoss, Ibrahim, Ali, Haris, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

14. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

15. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Author

Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu, Hogan, William J., Etra, Aaron, Choe, Hannah, Hexner, Elizabeth, Langston, Amelia, Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M., and Levine, John E.

Published
2023
Full Text
View/download PDF

16. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Author

Mei, Matthew, Palmer, Joycelynne, Tsai, Nicole Ni-Chun, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Al Malki, Monzr M., Herrera, Alex, Wong, Jeffrey, and Nademanee, Auayporn

Published
2023
Full Text
View/download PDF

17. Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

Author

Salhotra, Amandeep, Sandhu, Karamjeet S., Yang, Dongyun, Mokhtari, Sally, O’Hearn, James, Tegtmeier, Bernard, Al Malki, Monzr M., Abella, Justine, Meguro, Akemi, Dickter, Jana, Khambapati, Swetha, Spielberger, Ricardo, Artz, Andrew, Forman, Stephen J., Smith, Eileen, Nakamura, Ryotaro, and Dadwal, Sanjeet S.

Published
2023
Full Text
View/download PDF

18. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

Author

Al Malki, Monzr M, Yang, Dongyun, Labopin, Myriam, Afanasyev, Boris, Angelucci, Emanuele, Bashey, Asad, Socié, Gérard, Karduss-Urueta, Amado, Helbig, Grzegorz, Bornhauser, Martin, Niittyvuopio, Riitta, Ganser, Arnold, Ciceri, Fabio, Brecht, Arne, Koc, Yener, Bejanyan, Nelli, Ferraro, Francesca, Kebriaei, Partow, Mokhtari, Sally, Ghobadi, Armin, Nakamura, Ryotaro, Forman, Stephen J, Champlin, Richard, Mohty, Mohamad, Ciurea, Stefan O, and Nagler, Arnon

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Transplantation, Hematology, Stem Cell Research, Clinical Research, Stem Cell Research - Nonembryonic - Human, Rare Diseases, Pediatric Research Initiative, Good Health and Well Being, Adult, Cyclophosphamide, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Unrelated Donors, Cardiovascular medicine and haematology
Abstract

We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL) receiving hematopoietic cell transplantation (HCT) from a haploidentical (n = 487) or matched unrelated donor (MUD; n = 974) between January 2005 and June 2018. Graft-versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy), calcineurin inhibitor (CNI), and mycophenolate mofetil (MMF) for haploidentical, and CNI with MMF or methotrexate with/without antithymoglobulin for MUDs. Haploidentical recipients were matched (1:2 ratio) with MUD controls for sex, conditioning intensity, disease stage, Philadelphia-chromosome status, and cytogenetic risk. In the myeloablative setting, day +28 neutrophil recovery was similar between haploidentical (87%) and MUD (88%) (P = .11). Corresponding rates after reduced-intensity conditioning (RIC) were 84% and 88% (P = .47). The 3-month incidence of grade II-IV acute GVHD (aGVHD) and 3-year chronic GVHD (cGVHD) was similar after haploidentical compared with MUD: myeloablative conditioning, 33% vs 34% (P = .46) for aGVHD and 29% vs 31% for cGVHD (P = .58); RIC, 31% vs 30% (P = .06) for aGVHD and 24% vs 29% for cGVHD (P = .86). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 44% and 51% with haploidentical and MUD (P = .56). Corresponding rates after RIC were 43% and 42% (P = .6). In this large multicenter case-matched retrospective analysis, despite the limitations of a registry-based study (ie, unavailability of key elements such as minimal residual disease testing), our analysis indicated that outcomes of patients with ALL undergoing HCT from a haploidentical donor were comparable with 8 of 8 MUD transplantations.

Published
2020

19. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Author

Solomon, Scott, St Martin, Andrew, Shah, Nirav, Fatobene, Giancarlo, Al Malki, Monzr, Ballen, Karen, Bashey, Asad, Bejanyan, Nelli, Bolaños Meade, Javier, Brunstein, Claudio, DeFilipp, Zachariah, Champlin, Richard, Fuchs, Ephraim, Hamadani, Mehdi, Hematti, Peiman, Kanakry, Christopher, McGuirk, Joseph, McNiece, Ian, Ciurea, Stefan, Pasquini, Marcelo, Rocha, Vanderson, Romee, Rizwan, Patel, Sagar, Vasu, Sumithira, Waller, Edmund, Wingard, John, Zhang, Mei-Jie, and Eapen, Mary

Subjects
Adolescent, Adult, Disease-Free Survival, Female, Hematologic Neoplasms, Humans, Middle Aged, Myeloablative Agonists, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

In the absence of prospective studies that examine the effect of conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of the 1325 eligible patients (AML, n = 818; ALL, n = 286; and MDS, n = 221), 526 patients received a myeloablative regimen and 799 received a reduced-intensity regimen. Graft-versus-host disease prophylaxis was uniform with posttransplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil. The primary end point was disease-free survival. Cox regression models were built to study the effect of conditioning regimen intensity on transplant outcomes. For patients aged 18 to 54 years, disease-free survival was lower (hazard ratio [HR], 1.34; 42% vs 51%; P = .007) and relapse was higher (HR, 1.51; 44% vs 33%; P = .001) with a reduced-intensity regimen compared with a myeloablative regimen. Nonrelapse mortality did not differ according to regimen intensity. For patients aged 55 to 70 years, disease-free survival (HR, 0.97; 37% vs 43%; P = .83) and relapse (HR, 1.32; 42% vs 31%; P = .11) did not differ according to regimen intensity. Nonrelapse mortality was lower with reduced-intensity regimens (HR, 0.64; 20% vs 31%; P = .02). Myeloablative regimens are preferred for AML, ALL, and MDS; reduced-intensity regimens should be reserved for those unable to tolerate myeloablation.

Published
2019

20. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Author

Etra, Aaron, Capellini, Alexandra, Alousi, Amin, Al Malki, Monzr M., Choe, Hannah, DeFilipp, Zachariah, Hogan, William J., Kitko, Carrie L., Ayuk, Francis, Baez, Janna, Gandhi, Isha, Kasikis, Stelios, Gleich, Sigrun, Hexner, Elizabeth, Hoepting, Matthias, Kapoor, Urvi, Kowalyk, Steven, Kwon, Deukwoo, Langston, Amelia, Mielcarek, Marco, Morales, George, Özbek, Umut, Qayed, Muna, Reshef, Ran, Rösler, Wolf, Spyrou, Nikolaos, Young, Rachel, Chen, Yi-Bin, Ferrara, James L. M., and Levine, John E.

Published
2023
Full Text
View/download PDF

21. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Author

Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C., Al Malki, Monzr, Aribi, Ahmed, Agrawal, Vaibhav, Sandhu, Karamjeet, Salhotra, Amandeep, Pourhassan, Hoda, Koller, Paul, Ali, Haris, Artz, Andrew, Karras, Nicole, Pawlowska, Anna B., Murphy, Lindsey, Palmer, Joycelynne, Stein, Anthony, Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Forman, Stephen J.

Published
2024
Full Text
View/download PDF

22. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Author

Al Malki, Monzr M., primary, Bo-Subait, Stephanie, additional, Logan, Brent, additional, Olson, Janelle, additional, Leckrone, Erin, additional, Wu, Juan, additional, Stefanski, Heather E., additional, Auletta, Jeffery J., additional, Spellman, Stephen R., additional, Malmberg, Craig, additional, Shaffer, Brian C., additional, Modi, Dipenkumar, additional, Khimani, Farhad, additional, Gooptu, Mahasweta, additional, Hamadani, Mehdi, additional, Broglie, Larisa, additional, Shaw, Bronwen E., additional, Devine, Steven Michael, additional, and Jimenez Jimenez, Antonio Martin, additional

Published
2024
Full Text
View/download PDF

23. Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in myelofibrosis: Utility of 3D volumetrics in splenomegaly.

Author

Haseeb, Rafay, primary, Yang, Dongyun, additional, Motarjem, Pejman, additional, Al Malki, Monzr M., additional, Aldoss, Ibrahim, additional, Amanam, Idoroenyi Usua, additional, Otoukesh, Salman, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Rahmanuddin, Syed, additional, and Ali, Haris, additional

Published
2024
Full Text
View/download PDF

24. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Robbins, Marjorie, additional, Song, Joo, additional, Al Malki, Monzr M., additional, Otoukesh, Salman, additional, Sandhu, Karamjeet, additional, Agrawal, Vaibhav, additional, Herrera, Alex F., additional, Popplewell, Leslie L., additional, Ghoda, Lucy, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, and Pullarkat, Vinod, additional

Published
2024
Full Text
View/download PDF

26. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Author

Ghobadi, Armin, Slade, Michael, Kantarjian, Hagop, Alvarenga, Julio, Aldoss, Ibrahim, Mohammed, Kahee A., Jabbour, Elias, Faramand, Rawan, Shah, Bijal, Locke, Frederick, Fingrut, Warren, Park, Jae H., Short, Nicholas J., Gao, Feng, Uy, Geoffrey L., Westervelt, Peter, DiPersio, John F., Champlin, Richard E., Al Malki, Monzr M., Ravandi, Farhad, and Kebriaei, Partow

Published
2022
Full Text
View/download PDF

27. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Author

Dreger, Peter, Sureda, Anna, Ahn, Kwang, Eapen, Mary, Litovich, Carlos, Finel, Herve, Boumendil, Ariane, Gopal, Ajay, Herrera, Alex, Schmid, Christoph, Diez-Martin, José, Fuchs, Ephraim, Bolaños-Meade, Javier, Gooptu, Mahasweta, Al Malki, Monzr, Castagna, Luca, Ciurea, Stefan, Dominietto, Alida, Blaise, Didier, Ciceri, Fabio, Tischer, Johanna, Corradini, Paolo, Montoto, Silvia, Robinson, Stephen, Gülbas, Zafer, and Hamadani, Mehdi

Subjects
Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Retrospective Studies, Tissue Donors, Transplantation Conditioning, Young Adult
Abstract

This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor.

Published
2019

28. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Author

Aldoss, Ibrahim, Yang, Dongyun, Tomasian, Vanina, Mokhtari, Sally, Jackson, Ryan, Gu, Zhaohui, Telatar, Milhan, Yew, Hooi, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Mei, Matthew, Arslan, Shukaib, Koller, Paul, Artz, Andrew, Aoun, Patricia, Gu, Dongqing, Snyder, David, Stewart, Forrest M., Curtin, Peter, Stein, Anthony S., Pillai, Raju, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Nakamura, Ryotaro, and Afkhami, Michelle

Published
2022
Full Text
View/download PDF

31. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Author

Etra, Aaron, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Shah, Jay, Kowalyk, Steven, Ayuk, Francis, Baez, Janna, Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gandhi, Isha, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kapoor, Urvi, Kitko, Carrie L., Kraus, Sabrina, Lin, Jung-Yi, Al Malki, Monzr, Merli, Pietro, Pawarode, Attaphol, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Van Hyfte, Grace, Weber, Daniela, Wölfl, Matthias, Young, Rachel, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2022
Full Text
View/download PDF

33. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Author

Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., and Nakamura, Ryotaro

Published
2022
Full Text
View/download PDF

34. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author

Bhatt, Vijaya Raj, Wang, Tao, Chen, Karen, Kitko, Carrie L., MacMillan, Margaret L., Pidala, Joseph A., Al Malki, Monzr M., Badawy, Sherif M., Beitinjaneh, Amer, Ganguly, Siddhartha, Hamilton, Betty, Hildebrandt, Gerhard C., Lekakis, Lazaros J., Liu, Hongtao, Maziarz, Richard T., Modi, Dipenkumar, Murthy, Hemant S., Preussler, Jaime M., Sharma, Akshay, Spellman, Stephen R., Arora, Mukta, and Lee, Stephanie J.

Published
2022
Full Text
View/download PDF

35. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Koller, Paul, Tsai, Ni‐Chun, Yang, Dongyun, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Spielberger, Ricardo, Sahebi, Firoozeh, Al Malki, Monzr M., Cai, Ji‐Lian, Sandhu, Karamjeet S., Mansour, Joshua, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, and Marcucci, Guido

Published
2024
Full Text
View/download PDF

36. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.

Author

Tinajero, Jose, Ngo, Dat, Zhang, Jianying, Tsai, Ni-Chun, Aribi, Ahmed, Aldoss, Ibrahim, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Pourhassan, Hoda, Sandhu, Karamjeet, Al-Malki, Monzr, Pullarkat, Vinod, Becker, Pamela, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Artz, Andrew, Koller, Paul, and Salhotra, Amandeep

Subjects
ACUTE myeloid leukemia, OLDER patients
Abstract

This document presents data on the outcomes and toxicities of a treatment regimen for older adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The study found that the treatment approach, which included induction chemotherapy with the addition of midostaurin, resulted in a high complete remission rate and a median overall survival of 9.3 months. Additionally, a significant number of patients underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with favorable outcomes. The authors conclude that this treatment approach is feasible and effective for older adults with FLT3-mutated AML. However, the study lacked long-term follow-up and data on minimal residual disease achievement and allo-HCT outcomes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

37. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer.

Author

Pourhassan, Hoda, Zhang, Jianying, Tinajero, Jose, Pullarkat, Vinod, Agrawal, Vaibhav, Koller, Paul, Al Malki, Monzr, Aribi, Ahmed, Salhotra, Amandeep, Sandhu, Karamjeet, Ali, Haris, Stein, Anthony, Marcucci, Guido, Forman, Stephen, and Aldoss, Ibrahim

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, BREAST cancer, CARCINOGENS, PHILADELPHIA chromosome
Abstract

Summary: Therapy‐related acute lymphoblastic leukaemia (tr‐ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr‐ALL, likely due to high prevalence and excellent curable rate for non‐metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse‐free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr‐ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr‐ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

Author

Elmariah, Hany, Otoukesh, Salman, Kumar, Ambuj, Ali, Haris, Arslan, Shukaib, Shouse, Geoffrey, Pourhassan, Hoda, Nishihori, Taiga, Faramand, Rawan, Mishra, Asmita, Khimani, Farhad, Fernandez, Hugo, Lazaryan, Aleksandr, Nieder, Michael, Perez, Lia, Liu, Hien, Nakamura, Ryotaro, Pidala, Joseph, Marcucci, Guido, Forman, Stephen J., Anasetti, Claudio, Locke, Frederick, Bejanyan, Nelli, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

40. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Author

Mac, Stephanie, Ngo, Dat, Yang, Dongyun, Chen, Jason, Ali, Haris, Arslan, Shukaib, Dadwal, Sanjeet, Salhotra, Amandeep, Cao, Thai, Karras, Nicole, Aldoss, Ibrahim, Koller, Paul, Artz, Andrew, Aribi, Ahmed, Sandhu, Karamjeet, Pullarkat, Vinod, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2021
Full Text
View/download PDF

41. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.

Author

Kanate, Abraham S, DiGilio, Alyssa, Ahn, Kwang W, Al Malki, Monzr, Jacobsen, Eric, Steinberg, Amir, Hamerschlak, Nelson, Kharfan-Dabaja, Mohamed, Salit, Rachel, Ball, Edward, Bashir, Qaiser, Cashen, Amanda, Couriel, Daniel, Diez-Martin, Jose, Katsanis, Emmanuel, Linhares, Yulia, Mori, Shahram, Nash, Richard, Pawarode, Attaphol, Perales, Miguel-Angel, Phipps, Colin D, Richman, Carol, Savani, Bipin N, Shapira, Michael Y, Stiff, Patrick, Strair, Roger, Fenske, Timothy S, Smith, Sonali M, Sureda, Anna, Olteanu, Horatiu, and Hamadani, Mehdi

Subjects
Humans, Nose Neoplasms, Treatment Outcome, Salvage Therapy, Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Registries, Survival Analysis, Retrospective Studies, Follow-Up Studies, Adult, Aged, Middle Aged, Female, Male, Lymphoma, Extranodal NK-T-Cell, Young Adult, allogeneic haematopoietic cell transplantation, extranodal NK/T-cell lymphoma, non-relapse mortality, relapse, survival, Transplantation, Homologous, Lymphoma, Extranodal NK-T-Cell, Immunology, Cardiorespiratory Medicine and Haematology
Published
2018

42. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation

Author

Dickter, Jana K., primary, Aribi, Ahmed, additional, Cardoso, Angelo A., additional, Gianella, Sara, additional, Gendzekhadze, Ketevan, additional, Li, Shirley, additional, Feng, Ye, additional, Chaillon, Antoine, additional, Laird, Gregory M., additional, Browning, Diana L., additional, Ross, Justine A., additional, Nanayakkara, Deepa D., additional, Puing, Alfredo, additional, Stan, Rodica, additional, Lai, Lily L., additional, Chang, Sue, additional, Kadambi, Trilokesh D., additional, Thomas, Sandra, additional, Al Malki, Monzr M., additional, Nakamura, Ryo, additional, Alvarnas, Joseph, additional, Taplitz, Randy A., additional, Dadwal, Sanjeet S., additional, Forman, Stephen J., additional, and Zaia, John A., additional

Published
2024
Full Text
View/download PDF

43. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Author

Nakamura, Ryotaro, primary, La Rosa, Corinna, additional, Yang, Dongyun, additional, Hill, Joshua A., additional, Rashidi, Armin, additional, Choe, Hannah, additional, Zhou, Qiao, additional, Lingaraju, Chetan Raj, additional, Kaltcheva, Teodora, additional, Longmate, Jeffrey, additional, Drake, Jennifer, additional, Slape, Cynthia, additional, Duarte, Lupe, additional, Al Malki, Monzr M., additional, Pullarkat, Vinod A., additional, Aribi, Ahmed, additional, Devine, Steven, additional, Verneris, Michael R., additional, Miller, Jeffrey S., additional, Forman, Stephen J., additional, Aldoss, Ibrahim, additional, and Diamond, Don J., additional

Published
2024
Full Text
View/download PDF

44. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

Author

Akahoshi, Yu, primary, Spyrou, Nikolaos, additional, Hoepting, Matthias, additional, Aguayo-Hiraldo, Paibel, additional, Ayuk, Francis Ayuketang, additional, Chanswangphuwana, Chantiya, additional, Choe, Hannah K, additional, Eder, Matthias, additional, Etra, Aaron M., additional, Grupp, Stephan A., additional, Hexner, Elizabeth O., additional, Hogan, William J, additional, Kitko, Carrie L., additional, Kraus, Sabrina, additional, Al Malki, Monzr M, additional, Merli, Pietro, additional, Qayed, Muna, additional, Reshef, Ran, additional, Schechter-Finkelstein, Tal, additional, Ullrich, Evelyn, additional, Vasova, Ingrid, additional, Wölfl, Matthias, additional, Zeiser, Robert, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Eng, Gilbert W, additional, Gleich, Sigrun, additional, Kasikis, Stelios, additional, Katsivelos, Nikolaos, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Rachel, additional, DeFilipp, Zachariah, additional, Ferrara, James L.M., additional, Levine, John E, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

45. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Author

Salhotra, Amandeep, primary, Yang, Dongyun, additional, Mokhtari, Sally, additional, Modi, Badri, additional, Al Malki, Monzr M., additional, Ali, Haris, additional, Amanam, Idoroenyi, additional, Karras, Nicole, additional, Sandhu, Karamjeet S., additional, Aribi, Ahmed, additional, Otoukesh, Salman, additional, Artz, Andrew S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Smith, Eileen, additional, Zeng, Defu, additional, Rosen, Steven, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

46. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Author

Salhotra, Amandeep, primary, Bejanyan, Nelli, additional, Yang, Dongyun, additional, Mokhtari, Sally, additional, Al Malki, Monzr M., additional, Sandhu, Karamjeet S., additional, Faramand, Rawan G, additional, Aldoss, Ibrahim, additional, Artz, Andrew S., additional, Aribi, Ahmed, additional, Elmariah, Hany, additional, Sahebi, Firoozeh, additional, Mansour, Joshua, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Li, Ling, additional, Pullarkat, Vinod, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Stein, Anthony S., additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

47. Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Acute Leukemia or MDS

Author

Auletta, Jeffery J., primary, Al Malki, Monzr M., additional, DeFor, Todd E., additional, Shaffer, Brian C., additional, Gooptu, Mahasweta, additional, Meade, Javier Bolaños, additional, Abboud, Ramzi, additional, Briggs, Adrienne, additional, Khimani, Farhad, additional, Modi, Dipenkumar, additional, Newcomb, Richard Andrew, additional, Shpall, Elizabeth J., additional, Bupp, Caitrin, additional, Spellman, Stephen R., additional, Stefanski, Dr. Heather E., additional, Jimenez Jimenez, Antonio M, additional, and Devine, Steven M., additional

Published
2024
Full Text
View/download PDF

48. TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial

Author

Al Malki, Monzr M., primary, Keyzner, Alla, additional, Suh, Hyung C., additional, Popat, Uday R., additional, Dwivedi, Nishant, additional, Kothari, Ashish S, additional, Buonomo, Erica, additional, Wang, Yun, additional, Abelowitz, Nina, additional, Murray, Jim, additional, MacBeath, Gavin, additional, Barton, Debora, additional, Chattopadhyay, Shrikanta, additional, and Reshef, Ran, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results